Protective effect of alpha7 nAChR: Behavioural and morphological features on neuropathy

Pacini, Alessandra; Mannelli, Lorenzo Di Cesare; Bonaccini, Laura; Ronzoni, Silvano; Bartolini, Alessandro; Ghelardini, Carla

doi:10.1016/j.pain.2010.06.014

Cited by 51 publications

(47 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This model evoked a pain syndrome characterized by increased response to a suprathreshold stimulation that begins about 3 days after nerve injury and reaches a plateau that lasts between 7 and 30 days [38]. In our experiments, we started the laser treatments 1 week after injury.…”

Section: Discussionmentioning

confidence: 99%

Photobiomodulation therapy by NIR laser in persistent pain: an analytical study in the rat

et al. 2017

Self Cite

View full text Add to dashboard Cite

Over the past three decades, physicians have used laser sources for the management of different pain conditions obtaining controversial results that call for further investigations. In order to evaluate the pain relieving possibilities of photobiomodulation therapy (PBMT), we tested two near infrared (NIR) laser systems, with different power, against various kinds of persistent hyperalgesia animal models. In rats, articular pain was reproduced by the intra-articular injection of sodium monoiodoacetate (MIA) and complete Freund's adjuvant (CFA), while compressive neuropathy was modelled by the chronic constriction injury of the sciatic nerve (CCI). In MIA and CFA models, (NIR) laser (MLS-Mphi, ASA S.r.l., Vicenza, Italy) application was started 14 days after injury and was performed once a day for a total of 13 applications. In MIA-treated animals, the anti-hyperalgesic effect of laser began 5 min after treatment and vanished after 60 min. The subsequent applications evoked similar effects. In CFA-treated rats, laser efficacy started 5 min after treatment and disappeared after 180 min. In rats that underwent CCI, two treatment protocols with similar fluence but different power output were tested using a new experimental device called Multiwave Locked System laser (MLS-HPP). Treatments began 7 days after injury and were performed during 3 weeks for a total of 10 applications. Both protocols reduced mechanical hyperalgesia and hindlimb weight bearing alterations until 60 min after treatment with a higher efficacy recorded for the animals treated using the higher power output. In conclusion, this study supports laser therapy as a potential treatment for immediate relief of chronic articular or neuropathic pain.

show abstract

Section: Discussionmentioning

confidence: 99%

Photobiomodulation therapy by NIR laser in persistent pain: an analytical study in the rat

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Among the pentameric ligand-gated ion channel proteins, two nicotinic receptor subtypes are known to be mainly involved in pain modulation, i.e., the heteromeric α4β2 and the homomeric α7 receptor. [28][29][30] The α7 nicotinic receptor agonist alleviated an inflammatory pain.…”

Section: Discussionmentioning

confidence: 99%

Nicotinic Acetylcholine Receptors Mediate the Suppressive Effect of an Injection of Diluted Bee Venom into the GV3 Acupoint on Oxaliplatin-Induced Neuropathic Cold Allodynia in Rats

Yoon

Kim

Yoon

et al. 2015

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Oxaliplatin, a platinum-based chemotherapy drug, often induces acute neuropathic pain, especially cold allodynia, even after a single administration. Subcutaneous injection of diluted bee venom (BV) into acupoints has been used to treat various pain symptoms in traditional oriental medicine. Although we previously demonstrated the suppressive effect of BV injection on oxaliplatin-induced cold allodynia in rats, its neurochemical mechanism remained unclear. This study investigates whether and how the cholinergic system mediates the relieving effect of BV injection on cold allodynia in oxaliplatin-administered rats. The behavioral signs of cold allodynia induced by an oxaliplatin administration (6 mg/kg, intraperitoneally (i.p.)) were evaluated by a tail immersion test in cold water (4°C). BV (0.25 mg/kg, subcutaneously (s.c.)) injection into the Yaoyangguan acupoint, located between the spinous processes of the fourth and fifth lumbar vertebrae, significantly alleviated the cold allodynia. This relieving effect of BV injection on oxaliplatin-induced cold allodynia was blocked by a pretreatment with mecamylamine (a non-selective nicotinic receptor antagonist, 2 mg/kg, i.p.), but not by atropine (a non-selective muscarinic receptor antagonist, 1 mg/kg, i.p.). Further, dihydro-β-erythroidinehydrobromide (DHβE, an α4β2 nicotinic antagonist, 5 mg/kg, i.p.) prevented the antiallodynic effect of BV, whereas methyllycaconitine (an α7 nicotinic antagonist, 6 mg/kg, i.p.) did not. Finally, intrathecal administration of DHβE (10 nM) blocked the BV-induced anti-allodynic effect. These results suggest that nicotinic acetylcholine receptors, especially spinal α4β2 receptors, but not muscarinic receptors, mediate the suppressive effect of BV injection on oxaliplatin-induced acute cold allodynia in rats.Key words oxaliplatin; bee venom; cholinergic; cold allodynia; nicotinic receptor; rat Oxaliplatin is a third-generation platinum-based chemotherapy drug for advanced colorectal cancer.1) Unlike the other platinum compounds (e.g. cisplatin and carboplatin), oxaliplatin does not induce nephrotoxicity and hepatotoxicity, but often induces a very acute painful neuropathy soon after an administration.2) This acute neuropathy is the only major dose-limiting toxicity associated with oxaliplatin use 3) and is characterized by the rapid onset of cold-induced peripheral dysesthesia, paresthesia, or hypoesthesia of the hands, feet, or throat. 4,5) Previous animal studies also have shown that a single administration of oxaliplatin (6 mg/kg, intraperitoneally (i.p.)) reproduces the neurotoxic profile, especially cold allodynia.6,7) However, its mechanism is still unclear and an effective treatment of established neuropathic cold allodynia remains to be found. 8)A subcutaneous injection of diluted bee venom (BV) into acupoints, so called 'bee venom acupuncture,' has been used as a part of traditional oriental medicine to relieve pain and treat various diseases, such as arthritis, rheumatism, cancer, asthma and skin diseases.9-11) It is a kind...

show abstract

“…Moreover, maca-dependent pain relief allows also to reduce postural unbalance, an outward of osteoarthritis progression, as measured by hind limb weight bearing alterations [34]. The antineuropathic properties of the L. meyenii extract are confirmed after the ligation of the sciatic nerve, a neuropathy model where the alterations of the nerve morphology are accompanied by remarkable inflammatory state emerged in terms of cellular infiltrate and edema [37,38]. Maca extract, at maximum dosage, is able to revert mechanical hypersensitivity for 30 Paclitaxel + Lepidium meyenii 1.5 g kg -1 Paclitaxel + Lepidium meyenii 3 g kg -1 Paclitaxel + Lepidium meyenii 10 g kg -1 Oxaliplatin + Vehicle Oxaliplatin + Lepidium meyenii 0.5 g kg -1 Oxaliplatin + Lepidium meyenii 3 g kg -1 Oxaliplatin + Lepidium meyenii 10 g kg -1 Oxaliplatin + Lepidium meyenii 1. )…”

Section: Discussionmentioning

confidence: 97%

Effects of a water extract of Lepidium meyenii root in different models of persistent pain in rats

Tenci

Mannelli

Maresca

et al. 2017

Zeitschrift Für Naturforschung C

Self Cite

View full text Add to dashboard Cite

Lepidium meyenii (Walp.), commonly called maca, is an Andean crop belonging to the Brassicaceae family. Maca hypocotils are habitually consumed as customary food as well as traditional remedies for pathological conditions such as infertility. Moreover, the characterization of maca extracts revealed the presence of compounds that are able to modulate the nervous system. Aimed to evaluate the efficacy of L. meyenii in persistent pain, the present study analyzed the effects of a commercial root extract from maca in different animal models reproducing the most common causes of chronic painful pathologies. A qualitative characterization of this commercial extract by high performance liquid chromatography-mass spectrometry and tandem mass spectrometry analyses allowed us to confirm the presence of some macamides known as bioactive constituents of this root and the absence of the main aromatic glucosinolates. The acute oral administration of maca extract is able to reduce mechanical hypersensitivity and postural unbalance induced by the intra-articular injection of monoiodoacetate and the chronic-constriction injury of the sciatic nerve. Furthermore, L. meyenii extract reverts pain threshold alterations evoked by oxaliplatin and paclitaxel. A good safety profile in mice and rats was shown. In conclusion, the present maca extract could be considered as a therapeutic opportunity to relieve articular and neuropathic pain.

show abstract

Protective effect of alpha7 nAChR: Behavioural and morphological features on neuropathy

Cited by 51 publications

References 50 publications

Photobiomodulation therapy by NIR laser in persistent pain: an analytical study in the rat

Photobiomodulation therapy by NIR laser in persistent pain: an analytical study in the rat

Nicotinic Acetylcholine Receptors Mediate the Suppressive Effect of an Injection of Diluted Bee Venom into the GV3 Acupoint on Oxaliplatin-Induced Neuropathic Cold Allodynia in Rats

Effects of a water extract of Lepidium meyenii root in different models of persistent pain in rats

Contact Info

Product

Resources

About